




PHARMACEUTICAL 2022

Scopus BioPharma Inc.
Rank 444 of 466





PHARMACEUTICAL 2022

Scopus BioPharma Inc.
Rank 444 of 466

The relative strengths and weaknesses of Scopus BioPharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Scopus BioPharma Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Scopus BioPharma Inc. is the variable Net Income, reducing the Economic Capital Ratio by 304% points.

The company's Economic Capital Ratio, given in the ranking table, is -325%, being 402% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	8,185
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,170
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-19
Other Expenses	0
Other Liabilities	0
Other Net Income	681
Other Revenues	0
Property and Equipment	2.8
Research and Development	15,023
Selling, General and Administrative Expense	12,611

Output Variable	Value in 1000 USD
Assets	8,188
Liabilities	4,170
Expenses	27,635
Revenues	0
Stockholders Equity	4,017
Net Income	-26,953
Comprehensive Net Income	-26,963
Economic Capital Ratio	-325%